Regulatory T cells and type 2 innate lymphoid cell-dependent asthma

Area of Science:

• Immunology
• Cell Biology
• Respiratory Medicine

Background:

• Group 2 innate lymphoid cells (ILC2s) are key drivers of Type 2 (Th2) inflammatory responses.
• Pulmonary ILC2 activation contributes to asthma pathogenesis, including eosinophilia and airway hyper-reactivity.
• ILC2s are implicated in the persistence and exacerbation of asthma in human subjects.

Purpose of the Study:

• To investigate the regulatory mechanisms of pulmonary ILC2 activation.
• To explore the potential of induced regulatory T cells (iTregs) in modulating ILC2 function.
• To identify therapeutic targets for ILC2-mediated allergic lung diseases.

Main Methods:

• Investigated the suppressive capacity of iTregs on ILC2 cytokine production (IL-5, IL-13).
• Assessed the role of direct cell-cell contact and the ICOS-ICOSL pathway in iTreg-mediated inhibition.
• Examined the impact of cytokines like IL-10 and TGF-β1 on ILC2 activity.

Main Results:

• iTregs effectively suppress the production of pro-inflammatory cytokines IL-5 and IL-13 by ILC2s.
• iTreg-mediated inhibition of ILC2s is dependent on direct cellular contact and the ICOS-ICOSL pathway.
• IL-10 and TGF-β1 also demonstrate inhibitory effects on ILC2 cytokine secretion.

Conclusions:

• iTregs are potent regulators of ILC2 activation and function.
• The ICOS-ICOSL pathway is crucial for iTreg-mediated suppression of ILC2s.
• Targeting iTregs presents a potential therapeutic strategy for allergic asthma and other ILC2-driven respiratory diseases.